BLAINJECTIONINJECTABLE
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ZARXIO (filgrastim-sndz) by Novartis. Approved for leukocyte growth factor [epc]. First approved in 2015.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZARXIO (filgrastim-sndz) is a biosimilar granulocyte colony-stimulating factor (G-CSF) indicated for leukocyte growth support in patients undergoing chemotherapy or hematopoietic stem cell transplantation. It works by stimulating the production and release of neutrophils from bone marrow to reduce infection risk in immunocompromised patients. The drug is administered by injection and represents a cytokine-based biologic therapy.
$47MPart D
PeakStable
ZARXIO remains at peak commercial performance with $47M in Part D spending; teams are likely focused on defending market share against biosimilar and competing G-CSF products.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZARXIO connects you to Novartis's established oncology supportive care franchise and mature biologic manufacturing/regulatory operations. Roles span R&D (analytical, formulation, CMC) and Legal, reflecting post-approval lifecycle management and compliance demands.
Scientist IIScientist
Worked on ZARXIO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.